COVID-19
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 27, 2020.
It was a busy week for clinical trial news, with some very important early-stage trial data for various COVID-19 vaccines. Here’s a look.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
An antiviral drug, favipiravir, developed by Glenmark Pharmaceuticals, boosted the time it takes COVID-19 patients with mild to moderate symptoms to improve their health in a Phase III study.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 24, 2020.
Francis Collins, the director of the NIH, told STAT they were “really well-powered, rigorously designed clinical trials.”
“Hopefully the approval process will go very quickly, and we think we have a winner here,” Trump told White House reporters on Wednesday.
How long do antibodies against SARS-CoV-2, the novel coronavirus that causes the disease, last? And if they are gone, is your immune system still able to offer protection against getting infected again?
Only days after announcing a COVID-19 vaccine production deal with the UK government, New York-based Pfizer and Germany-based BioNTech signed an even bigger deal with the U.S. government.
In an ongoing online hearing before the House Committee on Energy and Commerce’s Oversight and Investigation subcommittee, executives from across the pharmaceutical industry outlined the steps their companies are taking to combat COVID-19 and restore the world to a sense of normalcy.
PRESS RELEASES